Special Issue "Current and Future Research in Immunotherapy for Brain Tumors"
Deadline for manuscript submissions: 10 September 2022 | Viewed by 548
Immunotherapy has revolutionized cancer treatment. In recent years, immunooncologic (OI) therapies have become standard of care for several cancers, and potential additional indications are being explored through clinical trials. The development of effective IO strategies in neuro-oncology has been met with several distinct challenges, given the distinct biology of nervous system tumours and the brain itself. Dedicated clinical and preclinical efforts to best understand how to harness these therapies to treat nervous system cancers are ongoing.
Topics explored in this issue will include, but will not be limited to, the following:
Scope of work:
- The immunobiology of CNS tumours
- Translational models of immunotherapy for brain tumours
- Unique challenges and considerations in designing clinical trials for immunotherapy in neuro-oncology
- Clinical research in immunooncology for brain tumours: insights gained, current efforts, future directions
- Current practices and potential applications of immunotherapy in specific CNS cancer populations
- Diffuse glioma
- Rare tumours
- Pediatric brain tumours
- Brain metastases
Dr. Rebecca Harrison
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.